FDA Grants RMAT Designation to Allogene's Cema-Cel for First-Line Lymphoma
ALLO sits 69% above its 52-week low of $0.984.
Summary
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allogene's off-the-shelf CAR T therapy cema-cel for first-line consolidation in large B-cell lymphoma. This designation provides expedited development and review benefits, including early FDA interactions and potential priority review. The company also reported no treatment-related serious adverse events or high-grade infections, reinforcing a favorable safety profile. This follows positive interim Phase 2 ALPHA3 data reported in May and an executive transition to a new CEO. With a $573M market cap and cash runway into 2029, the RMAT designation strengthens the regulatory path and could accelerate time to market for a therapy addressing a significant unmet need.
At the time of this announcement, ALLO was trading at $1.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $573M. The 52-week trading range was $0.98 to $4.46. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.